Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Purchased by Millennium Management LLC

Millennium Management LLC grew its holdings in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 224.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 76,123 shares of the company's stock after acquiring an additional 52,628 shares during the period. Millennium Management LLC owned about 0.14% of Fulcrum Therapeutics worth $358,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of FULC. Bank of New York Mellon Corp lifted its position in shares of Fulcrum Therapeutics by 2.3% during the fourth quarter. Bank of New York Mellon Corp now owns 141,873 shares of the company's stock worth $667,000 after purchasing an additional 3,126 shares during the last quarter. American Century Companies Inc. lifted its position in shares of Fulcrum Therapeutics by 5.9% during the fourth quarter. American Century Companies Inc. now owns 120,611 shares of the company's stock worth $567,000 after purchasing an additional 6,770 shares during the last quarter. BNP Paribas Financial Markets bought a new position in shares of Fulcrum Therapeutics during the fourth quarter worth about $38,000. Wells Fargo & Company MN lifted its position in shares of Fulcrum Therapeutics by 34.4% during the fourth quarter. Wells Fargo & Company MN now owns 34,264 shares of the company's stock worth $161,000 after purchasing an additional 8,761 shares during the last quarter. Finally, Intech Investment Management LLC lifted its position in shares of Fulcrum Therapeutics by 74.9% during the fourth quarter. Intech Investment Management LLC now owns 30,499 shares of the company's stock worth $143,000 after purchasing an additional 13,057 shares during the last quarter. 89.83% of the stock is currently owned by institutional investors and hedge funds.

Fulcrum Therapeutics Stock Performance

Shares of FULC traded up $0.07 during mid-day trading on Friday, reaching $6.85. 247,184 shares of the company's stock traded hands, compared to its average volume of 965,833. The business's 50-day moving average price is $5.23 and its 200-day moving average price is $4.28. The stock has a market capitalization of $369.76 million, a P/E ratio of -22.10 and a beta of 2.41. Fulcrum Therapeutics, Inc. has a 12 month low of $2.32 and a 12 month high of $10.13.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported ($0.28) earnings per share for the quarter, beating analysts' consensus estimates of ($0.29) by $0.01. Equities research analysts anticipate that Fulcrum Therapeutics, Inc. will post -0.16 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently commented on FULC shares. Leerink Partnrs raised shares of Fulcrum Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Friday, May 23rd. Cantor Fitzgerald raised shares of Fulcrum Therapeutics from a "neutral" rating to an "overweight" rating and set a $10.00 target price on the stock in a report on Thursday, May 15th. Leerink Partners raised shares of Fulcrum Therapeutics from a "market perform" rating to an "outperform" rating and raised their target price for the stock from $4.00 to $12.00 in a report on Friday, May 23rd. Piper Sandler reissued an "overweight" rating and issued a $9.00 target price (up previously from $6.00) on shares of Fulcrum Therapeutics in a report on Thursday, May 29th. Finally, HC Wainwright reissued a "neutral" rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a report on Wednesday, February 26th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, three have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $6.29.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.